Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Biotechnology

Healthcare
$8.44 +3.04%

+$0.26 today

Market cap
$547.12M
Beta
1.80
P/E (TTM)
-1.7
EPS (TTM)
-$5.11
52W Low $5.37High $17.58

Volume 2.36M

Average 1.24M

DNA Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Ginkgo Bioworks Holdings, Inc.NYSE: DNA

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables turns negative

Q1 FY2026 accounts payables was -$11.6M, compared with $6.42M a year earlier. Trailing-twelve-month accounts payables was -$43.13M. Over 3 fiscal years it compounded at -34.9% a year.

Context

  • Accounts payables amounted to 1.8% of revenue in FY2025, down 0.3 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly accounts payables holds near -$11.6M or moves back toward the trailing-twelve-month quarterly average of -$10.78M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$11.6M-41.9% QoQ
Last fiscal yearDec 2025
-$2.99M-162.7% YoY
LTMMar 2026
-$43.13M-13619.7% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-280.7%——
1 year-162.7%——
3-year CAGR-34.9%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(2.99M) USD
Year-over-year change
-162.7%

Accounts Payables vs competitors

How DNA compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -13619.7% is the lowest of 9, against a peer median of -32.3%.
  • Accounts payables amounts to 30.5% of revenue for DNA, versus a peer median of 1.3%.
DNA Competitors
Accounts Payables for DNA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 2026$43.13M USD-13619.7%-34.9%30.5%
ARVNArvinas, Inc.LTM Mar 2026$7.7M USD-527.8%—8.6%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$4.37M USD+2029.8%-8.6%—
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$3.74M USD-50.2%—1.0%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$3.05M USD+420.9%——
VIRVir Biotechnology, Inc.LTM Mar 2026$2.19M USD+169.7%+84.4%3.3%
MGTXMeiraGTx Holdings plcLTM Mar 2026$1.34M USD-154.2%—1.7%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$1.15M USD-14.3%+67.0%0.6%
REPLReplimune Group, Inc.LTM Dec 2025$654K USD-119.2%+107.2%—
VALNValneva SELTM Mar 2026€0 EUR——0.0%
Peer median (excluding DNA) —-32.3%+75.7%1.3%

Competitors are the stored peer set for DNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(1.84B)(2.11B)(892.87M)(547.03M)(312.76M)
Depreciation & Amortization29.08M42.55M71.55M63.02M58.99M
Deferred Income Tax30.21M(14.61M)(801K)(936K)(1.36M)
Stock-Based Compensation1.61B1.93B229.88M112.34M81.55M
Change in Working Capital(61.54M)(37.01M)29.84M(89.67M)(44.09M)
Accounts Receivables(114.09M)55.02M50.07M(4.73M)(1.47M)
Inventory(626K)164K000
Accounts Payables(2.25M)(10.84M)(1.18M)4.77M(2.99M)
Other Working Capital55.43M(81.35M)(19.05M)(89.72M)(39.62M)
Other Non-Cash Items(20.95M)(67.4M)266.9M142.69M46.62M
Operating Cash Flow(253.82M)(252.2M)(295.5M)(319.59M)(171.06M)
Capital Expenditures(56.52M)(52.27M)(40.8M)(62.54M)(7.67M)
Acquisitions (Net)(12.04M)26.65M(38.55M)(5.4M)0
Purchases of Investments(5M)(3.69M)00(418.63M)
Sales of Investments0004.52M185.38M
Other Investing Activities304K(38.08M)(1.34M)1.19M624K
Investing Cash Flow(73.26M)(67.39M)(80.69M)(62.24M)(240.29M)
Debt Repayment(1.12M)(1.24M)(1.3M)(897K)(354K)
Common Stock Issued099.3M080K19.47M
Common Stock Repurchased(25M)0(23K)00
Dividends Paid00000
Other Financing Activities1.56B(2.73M)(1.43M)(922K)(1.34M)
Financing Cash Flow1.53B95.34M(3.22M)(1.74M)17.78M
Effect of Forex Changes(19K)908K(588K)(281K)395K
Net Change in Cash1.21B(223.35M)(380M)(383.84M)(393.18M)
Free Cash Flow(310.34M)(304.47M)(336.3M)(382.13M)(178.72M)

Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Intrinsic Alpha fair value

Locked

Current Price

$8.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.